Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today.
Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.
Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $111M
Founded date: 2019
Investors 5
| Date | Name | Website |
| 29.05.2022 | Innovation... | innovation... |
| - | KdT Ventur... | kdtvc.com |
| 13.07.2025 | aMoon Fund | amoon.fund... |
| - | S32 | s32.com |
| 26.06.2022 | Lifeforce ... | lifeforcec... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.03.2025 | Series B | $93M | - |
| 17.05.2022 | - | $18M | - |
Mentions in press and media 6
| Date | Title | Description |
| 18.09.2025 | Character Biosciences Expands Series B Extension | Character Biosciences, Jersey City, NJ-based precision medicine company, raised an undisclosed amount in Series B extension. Backers included Sanofi Ventures. The company intends to use the funds to further advance the clinical development ... |
| 31.03.2025 | Character Biosciences: Pioneering Precision Medicine for Eye Diseases | In the realm of healthcare, precision medicine is the compass guiding us toward targeted therapies. Character Biosciences, a New Jersey-based company, is at the forefront of this revolution. Recently, they secured a hefty $93 million in Ser... |
| 28.03.2025 | Character Biosciences: $93 Million (Series B) Secured For Advancing Precision Medicine For Progressive Eye Diseases | Character Biosciences, a precision medicine company transforming drug development for polygenic diseases, announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies ... |
| 25.03.2025 | Character Biosciences Raises $93M in Series B Funding | Character Biosciences, a Jersey City, N.J.-based precision medicine company improving drug development for polygenic diseases, raised $93M in Series B funding. The round was led by aMoon and Luma Group, with additional participation from Ba... |
| 25.03.2025 | Character Biosciences lands $93M to lead pair of macular degeneration assets into the clinic | A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. Character Biosciences has landed a $93 million series B to progress its precision medicine candidates through clinical develop... |
| 17.05.2022 | Character Biosciences Raises $18M to Expand Precision Medicine Platform for Diseases of Aging | What You Should Know: – Character Biosciences (“Character”), a precision medicine platform for diseases of aging raises $18M in a new funding round led by Innovation Endeavors, alongside leading life sciences investors Section 32 and Catali... |